(MedPage Today) — SAN DIEGO — Two phase I/II studies showed that the investigational RAS(ON) inhibitor daraxonrasib had a manageable safety profile and demonstrated promising efficacy both in combination with chemotherapy and as monotherapy…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
